Skip to main content
SpringerLink
Log in

Insulinpumpentherapie 2010

Geräte und Anwendung

Insulin pump treatment 2010

Devices and application

  • CME Weiterbildung · Zertifizierte Fortbildung
  • Published:
Der Diabetologe Aims and scope

Zusammenfassung

Die kontinuierliche subkutane Insulininfusion (CSII) ist eine etablierte und in Leitlinien zur Behandlung von Patienten mit einem Typ-1-Diabetes unter definierten Bedingungen empfohlene Methode der Insulinsubstitution. Die Anwendung der CSII setzt Kenntnisse der Methode, der verwendeten Geräte, von Zubehör und Verbrauchsmaterialien, der speziellen Schulung, des Trainings, der Prozeduren beim Geräteentscheid, beim Pumpenstart und bei der Dauerbetreuung voraus.

Probleme und Komplikationen der CSII sind gegen Probleme und Komplikationen der diabetischen Situation als solcher abzugrenzen. CSII bei Sport, bei interkurrenten Erkrankungen, in der Schwangerschaft, im Alter und im Kindesalter erfordern besondere Beachtung.

Abstract

Continuous subcutaneous insulin infusion (CSII) is an established method for insulin substitution recommended in guidelines for the treatment of patients with type 1 diabetes under defined conditions. CSII application requires knowledge of the method, the devices used, accessories and supplies, a special education, training, the procedures of device selection, pump initiation, and continuous care.

Problems and complications of CSII must be weighed up against problems and complications of the diabetic state as such. CSII and sports, during concurrent diseases or pregnancy, in the elderly and childhood require special attention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Notes

  1. Die „NICE technology appraisal guidance 151“ vom Juli 2008 [34] definiert eine „disabling hypoglycemia“ „als das wiederholte und unvorhersehbare Auftreten von Hypoglykämien, die zu persistierender Angst über die Wiederholung führen und mit eindeutigen negativen Auswirkungen auf die Lebensqualität verbunden sind“.

Literatur

  1. American Diabetes Association (ADA) (2010) Standards of medical care in diabetes. Diabetes Care 33:S11–S61

    Article  Google Scholar 

  2. American Diabetes Association (ADA) (2010) Advantages of using an insulin pump. 13.3.2010, http://www.diabetes.org/living-with-diabetes/treatment-and-care/medication/insulin/advantages-of-using-an-insulin-pump

  3. American Diabetes Association (ADA) (2010) Disadvantages of using an insulin pump. 13.3.2010, http://www.diabetes.org/living-with-diabetes/treatment-and-care/medication/insulin/disadvantages-of-using-an-insulin-pump

  4. Bode B, Weinstein R, Bell D et al (2002) Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care 25:439–444

    Article  CAS  PubMed  Google Scholar 

  5. Bode BW, Steed RD, Schleusener DS, Strange P (2005) Switch to multiple daily injections with insulin glargine and insulin lispro from continuous subcutaneous insulin infusion with insulin lispro: a randomized, open-label study using a continuous glucose monitoring system. Endocr Pract 11:157–164

    PubMed  Google Scholar 

  6. Bode BW, Steed RD, Davidson PC (1997) Continuous subcutaneous insulin infusion (CSII): a study comparing lispro to regular human insulin. Diabetes 46 (Suppl 1):167A

    Google Scholar 

  7. Bolli GB, Kerr D, Thomas R, Torlone E et al (2009) Comparison of a multiple daily insulin injection regimen (basal once daily glargine plus mealtime lispro) and continuous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study. Diabetes Care 32:1170–1176

    Article  CAS  PubMed  Google Scholar 

  8. Colquitt J, Royle P, Waugh N (2003) Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis. Diabet Med 20:863–866

    Article  CAS  PubMed  Google Scholar 

  9. Colquitt JL, Green C, Sidhu MK et al (2004) Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. Health Technol Assess 8:1–171

    Google Scholar 

  10. Danne T, Lange K, Kordonouri O (2007) New developments in the treatment of type 1 diabetes in children. Arch Dis Child 92:1015–1019

    Article  PubMed  Google Scholar 

  11. Danne T, Pankowska E, Rami B et al (2009) The ONSET trial of sensor-enhanced CSII in children with new onset type 1 diabetes. 20th World Diabetes Congress, Montreal 2009, 0528 Abstract book:175

  12. Danne T, Schutz W von, Lange K et al (2006) Current practice of insulin pump therapy in children and adolescents – the Hannover recipe. Pediatr Diabetes 7 (Suppl 4):25–31

    Article  PubMed  Google Scholar 

  13. DeVries JH, Snoek FJ, Kostense PJ et al Dutch Insulin Pump Study Group (2002) A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care 25:2074–2080

    Article  CAS  PubMed  Google Scholar 

  14. Farrar D, Tuffnell DJ, West J (2007) Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Database Syst Rev 3:CD005542

    PubMed  Google Scholar 

  15. Habrich G (2009) Die Verordnung einer Insulinpumpe aus Sicht des MDK. Diabetologe 5:283–289

    Article  Google Scholar 

  16. Hammond P, Liebl A, Grunder S (2007) International survey of insulin pump users: Impact of continuous subcutaneous insulin infusion therapy on glucose control and quality of life. Prim Care Diabetes 1:143–146, Epub 2007 Aug 10

    Article  CAS  PubMed  Google Scholar 

  17. Henrichs HR (2003) Diabetestherapie mit Insulinpumpen – Die subkutane Insulininfusion. UNI-MED, Bremen/Intern Medical Publishers, London Boston (UNI-MED science)

  18. Henrichs HR, Liebl A, Reichel A et al (2009) Experimentelle Untersuchungen und klinische Evidenz der Insulinpumpentherapie (CSII). Diabetologie 4:390–397

    Article  Google Scholar 

  19. Henrichs HR, Schäfer D (1996) Deutsche Insulinpumpenträger Befragung. Pumpenforum, Sonderausgabe 5

  20. Hepp KD, Renner R, Funcke HL et al (1966) Glucose homeostasis under continuous intravenous insulin therapy in diabetics. Horm Metab Res 7 (Suppl):72–76

    Google Scholar 

  21. Hermanides J, Norgaard K, Bruttomesso D et al (2009) Sensor augmented pump therapy substantially lowers HbA1c; a randomized controlled trial. Diabetologia 52 (Suppl 1):S43

    Google Scholar 

  22. Hunger-Dathe W, Braun A, Muller UA et al (2003) Insulin pump therapy in patients with type 1 diabetes mellitus: results of the Nationwide Quality Circle in Germany (ASD) 1999–2000. Exp Clin Endocrinol Diabetes 111:428–434

    Article  CAS  PubMed  Google Scholar 

  23. Jeitler K, Horvath K, Berghold A et al (2008) Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia 51:941–951

    Article  CAS  PubMed  Google Scholar 

  24. Kadish AH (1964) Automation control of blood sugar I: A servomechanism for glucose monitoring and control. Am J Med Electron 39:82–86

    Google Scholar 

  25. Kleinwächter H, Bührer C, Hösli I et al (2009) Diabetes und Schwangerschaft. Diabetologia 4 (Suppl 2):187–193

    Article  Google Scholar 

  26. Kleinwächter H, Schäfer-Graf U (2008) Diabetes mellitus und Schwangerschaft. Diabetologie 3:R69–R93

    Article  Google Scholar 

  27. Klupa T, Benbenek-Klupa T, Malecki M et al (2008) Clinical usefulness of a bolus calculator in maintaining normoglycaemia in active professional patients with type 1 diabetes treated with continuous subcutaneous insulin infusion. J Int Med Res 36:1112–1116

    CAS  PubMed  Google Scholar 

  28. Knight S, Northam E, Donath S et al (2008) Improvements in cognition, mood and behaviour following commencement of continuous subcutaneous insulin infusion therapy in children with type 1 diabetes mellitus: a pilot study. Diabetologia 51:6

    Google Scholar 

  29. Kordonouri O (2009) Differentialindikationen und Relevanz der Pumpentherapie im Kindes- und Jugendalter. Diabetologe 5:258–264

    Article  Google Scholar 

  30. Liebl A (2009) Lösungsansätze bei frustraner Insulinpumpentherapie. Diabetologe 5:275–282

    Article  Google Scholar 

  31. Martin S, Dreyer M, Kiess W et al (2007) Evidenzbasierte Leitlinie der DDG – Therapie des Diabetes mellitus Typ 1 (Publiziert:05/2003, aktualisiert 05/2007), http://www.deutsche-diabetes-gesellschaft.de

  32. Monami M, Lamanna C, Marchionni N, Manucci E (2009) Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: a meta-analysis. Exp Clin Endocrinol Diabetes 117:220–222

    Article  CAS  PubMed  Google Scholar 

  33. Müller UA, Hunger-Dathe W, Müller N et al (2007) Insulinpumpentherapie für Erwachsene Langzeitglykämie und Hypoglykämien nach Teilnahme am strukturierten Behandlungs- und Schulungsprogramm „Insulinpumpen-Therapie für erwachsene Patienten mit Diabetes mellitus Typ 1“ von Roche Diagnostics GmbH. Diabetologie Stoffwechsel 2:161–168

    Article  Google Scholar 

  34. National Institute for Health and Clinical Excellence (NICE) (2008) NICE technology appraisal guidance 151

  35. O’Connell MA, Donath S, O’Neal DN et al (2009) Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial. Diabetologia 52:1250–1257

    Article  Google Scholar 

  36. Pickup J (2006) CSII from its beginning. DDG-AGDT-Symposium Leipzig

  37. Pickup J, Mattock M, Kerry S (2002) Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 324:705

    Article  CAS  PubMed  Google Scholar 

  38. Pickup JC, Hammond P (2009) NICE guidance on continuous subcutaneous insulin infusion 2008: review of the technology appraisal guidance. Diabet Med 26:1–4

    Article  CAS  PubMed  Google Scholar 

  39. Pickup JC, Keen H, Parsons JA, Alberti KG (1978) Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br Med J 1:204–207

    Article  CAS  PubMed  Google Scholar 

  40. Pickup JC, Sutton AJ (2008) Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 25:765–774

    Article  CAS  PubMed  Google Scholar 

  41. Ponder SW, Skyler JS, Kruger DF et al (2008) Unexplained hyperglycemia in continuous subcutaneous insulin infusion: evaluation and treatment. Diabetes Educ 34:327–333

    Article  PubMed  Google Scholar 

  42. Pouwer F, Hermanns N (2009) Insulin therapy and quality of life. A review. Diabetes Metab Res Rev 25(Suppl 1):S4–S10

    Article  CAS  PubMed  Google Scholar 

  43. Quester W, Kerner W, Fach EM et al (2009) Why to establish a pump registry in Germany? A comparison of MIT and CSII in 11,872 adult type 1-diabetics, based on a multicenter database. 20th World Congress IDF

  44. Raccah D, Sulmont V, Reznik Y et al (2009) Incremental value of continuous glukose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes. Diabetes Care 32:2245–2250

    Article  CAS  PubMed  Google Scholar 

  45. Renard E, Schaepelynck-Belicar P EVADIAC Group (2007) Implantable insulin pumps. A position statement about their clinical use. Diabetes Metab. 33:158–166

  46. Renner R, Lüddeke HJ, Hepp KD (1994) Analyse von Basalratenprofilen und Bolusabruf bezüglich HbA1c und Hypoglykämierate. Diabet Stoffw 3:178 Abstr T81

    Google Scholar 

  47. Renner R, Lüddeke HJ (1990) 77 Möglichkeiten und Risiken der Insulinpumpentherapie. Internist 31:226–235

    CAS  PubMed  Google Scholar 

  48. Renner R, Pfützner A, Trautmann M et al German Humalog-CSII Study Group (1999) Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. Diabetes Care 22:784–788

    Article  CAS  PubMed  Google Scholar 

  49. Retnakaran R, DeVries JH, Hanaire-Broutin H et al (2005) Continuous subcutaneous insulin infusion versus multiple daily injections: modeling predicted benefits in relationship to baseline A1c. Diabetes Care 28:1835–1836

    Article  PubMed  Google Scholar 

  50. Scuffham P, Carr L (2003) The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes. Diabet Med 20:586–593

    Article  CAS  PubMed  Google Scholar 

  51. Sengbusch S von, Heidtmann B, Burghoff C et al (2008) Insulinpumpenverordnung: Führt das starre, intransparente Genehmigungsverfahren zur (unbeabsichtigten) Vorenthaltung einer etablierten Diabetesbehandlung? Diabetologie 3:218–224

    Google Scholar 

  52. Shashaj B, Busetto E, Sulli N (2008) Benefits of a bolus calculator in pre- and postprandial glycaemic control and meal flexibility of paediatric patients using continuous subcutaneous insulin infusion (CSII). Diabet Med 25:1036–1042

    Article  CAS  PubMed  Google Scholar 

  53. Siebenhofer A, Plank J, Berghold A et al (2006) Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev CD003287

  54. Slama G, Hautecouverture M, Assan R, Tchobroutsky G (1974) One to five days of continuous intravenous insulin infusion on seven diabetic patients. Diabetes 23:732–738

    CAS  PubMed  Google Scholar 

  55. Thomas A (2006) Das Diabetesforschungsbuch, 2. Aufl. Kirchheim, Mainz

  56. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R (2003) Insulin pump therapy: a meta-analysis. Diabetes Care 26:1079–1087

    Article  PubMed  Google Scholar 

  57. Zinman B, Tildesley H, Chiasson JL et al (1997) Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 46:440–443

    Article  CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Wilhelmstr. 7, 49610, Quakenbrück, Deutschland

    H.R. Henrichs

Authors
  1. H.R. Henrichs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H.R. Henrichs.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Henrichs, H. Insulinpumpentherapie 2010. Diabetologe 6, 301–316 (2010). https://doi.org/10.1007/s11428-008-0279-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11428-008-0279-7

Schlüsselwörter

Keywords

Search

Navigation